Skip to main content
COX-2-specific inhibition: implications for clinical practice.
Journal of the American Osteopathic Association
  • Richard A. Pascucci, Philadelphia College of Osteopathic Medicine
Document Type
Publication Date
Although conventional nonsteroidal anti-inflammatory drugs (NSAIDs) have long been a major therapeutic choice for the management of arthritic conditions, the potential adverse effects of these agents sometimes compromise their clinical utility. New modes of therapy have recently been introduced, and data on the cyclooxygenase-2 (COX-2)-specific inhibitors celecoxib and rofecoxib suggest that these agents will meet the need for safe and effective therapeutic alternatives to conventional NSAIDs.

This article was published in Journal of the American Osteopathic Association, Volume 99, Issue 11 Suppl, Pages S18-22.

The published version is available at .

Copyright © 1999.

Citation Information
Richard A. Pascucci. "COX-2-specific inhibition: implications for clinical practice." Journal of the American Osteopathic Association Vol. 99 Iss. 11 Suppl (1999) p. S18 - 22
Available at: